natgillin/translations-raw huggingface dataset:
malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery; advanced non-small-cell lung cancer of the kind known as ‘non-squamous’, where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
malignog pleuralnog mezotelioma (rak ovojnice pluća koji je obično uzrokovan izlaganjem azbestu), pri čemu se koristi u kombinaciji s cisplatinom u bolesnika s neoperabilnim rakom koji prethodno nisu primali kemoterapiju; uznapredovalog raka pluća nemalih stanica pod nazivom „neskvamozne stanice”, pri čemu se koristi u kombinaciji s cisplatinom u prethodno neliječenih bolesnika ili kao monoterapija u bolesnika koji su prethodno primili terapiju protiv raka.
malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery; advanced non-small-cell lung cancer of the kind known as ‘non-squamous’, where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
malignog pleuralnog mezotelioma (rak ovojnice pluća koji je obično uzrokovan izlaganjem azbestu), pri čemu se koristi u kombinaciji s cisplatinom u bolesnika s neoperabilnim rakom koji prethodno nisu primali kemoterapiju; uznapredovalog raka pluća nemalih stanica vrste poznate pod nazivom „neskvamozne stanice”, kada se koristi u kombinaciji s cisplatinom u prethodno neliječenih bolesnika ili kao monoterapija u bolesnika koji su prethodno primili terapiju protiv raka.
malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery; advanced non-small-cell lung cancer of the kind known as ‘non-squamous’, where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
malignog pleuralnog mezotelioma (raka ovojnice pluća koji je obično uzrokovan izlaganjem azbestu), pri čemu se koristi u kombinaciji s cisplatinom u bolesnika koji prethodno nisu primali kemoterapiju i kod kojih se rak ne može kirurški odstraniti; uznapredovalog raka pluća nemalih stanica koje su poznate pod nazivom „neskvamozne stanice”, pri čemu se koristi ili u kombinaciji s cisplatinom u bolesnika koji prethodno nisu bili liječeni ili kao monoterapija u bolesnika koji su prethodno primili terapiju protiv raka.
malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery; advanced non-small-cell lung cancer of the kind known as ‘non-squamous’, where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
malignog pleuralnog mezotelioma (raka plućne ovojnice koji je obično uzrokovan izlaganjem azbestu), kada je u kombinaciji s cisplatinom indiciran za liječenje bolesnika s neoperabilnim malignim pleuralnim mezoteliomom koji prethodno nisu primili kemoterapiju; uznapredovalog raka pluća nemalih stanica poznatih pod nazivom „neskvamozne”, kada je u kombinaciji s cisplatinom indiciran za liječenje bolesnika koji prethodno nisu primili terapiju ili kao monoterapija za liječenje bolesnika koji su prethodno primili antitumorsku terapiju.
Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and and in the liver, urinary bladder, lymph nodes and the subcutis of females.
Maligni tumori javljali su se na prepucijskoj žlijezdi u mužjaka i klitoralnoj žlijezdi u ženki obje vrste, te u štakora na štitnoj žlijezdi mužjaka te u jetri, mokraćnom mjehuru, limfnim čvorovima i potkožnom tkivu u ženki.
mall area of inflammation
malo područje upale
mall bandage or sterile gauze
mali zavoj ili sterilna gaza
mall bumps at application site
kvržice na mjestu primjene
mall cell lung cancer that has come back after chemotherapy, or advanced cervical cancer if surgery or radiotherapy is not possible.
raka pluća malih stanica koji se ponovno pojavio nakon prethodne kemoterapije ili uznapredovalog raka vrata maternice ako kirurški zahvat ili zračenje nije moguće provesti.
mall cell lung cancer that has come back after chemotherapy.
raka pluća malih stanica koji se vratio nakon prethodne kemoterapije.
mall deposits on the eye or on the surface of the eye (cornea), deposits in the back of the eye,
male taloge na oku ili površini oka (rožnici), taloge u stražnjem dijelu oka
mall erosion on the central part of the surface of the eye (cornea)
malu eroziju središnjeg dijela površine oka (rožnice)
mall intestine
tanko crijevo
mall lump on your eyelid due to inflammation (chalazion)
malu kvržicu na vjeđi izazvanu upalom (halacion)
mall marks on the eye surface (punctate keratitis) small particles or spots in your vision (vitreous floaters or opacities).
male mrlje na površini oka (točkasti keratitis), male čestice ili točkice u vidnom polju (plutajuće čestice u staklovini i zamućenje staklovine).
mall red or purple spots caused by bleeding under the skin
male crvene ili ljubičaste točkice uzrokovane krvarenjem ispod kože
mall reduction in red blood cell count
malo sniženje broja crvenih krvnih stanica
mall reduction in red blood cell count
manje sniženje broja crvenih krvnih stanica
mall, dark shapes moving in the field of vision
mali, tamni oblici koji se pomiču u vidnom polju
Mallinckrodt Deutschland GmbH Josef-Dietzgen-Str.1
Mallinckrodt Deutschland GmbH Josef-Dietzgen-Str.
Malnutrition.
pothranjenost.
Malta
Hermesweg 15
Malta
Malta.
Malta
Uusaru 5
Malta
Ελλάδα
Malta (see United Kingdom )
Malta (vidjeti United Kingdom)
Maltodextrin
maltodekstrin
Maltol was transiently measured in plasma with a Cmax between 0.022 and 0.205 h.µg/mL across all dosing regimens and both study days.
Maltol je prolazno mjeren u plazmi s Cmax između 0,022 i 0,205 h.µg/mL u okviru svih režima doziranja i oba dana ispitivanja.
Manage Grade 4 liver laboratory abnormalities with treatment interruption, dose reduction or with treatment discontinuation of both Cotellic and vemurafenib (see section 4.2).
Odstupanja u laboratorijskim vrijednostima jetrenih parametara 4. stupnja treba zbrinuti privremenim prekidom liječenja, smanjenjem doze ili trajnom obustavom liječenja i lijekom Cotellic i vemurafenibom (vidjeti dio 4.2).
Management
Liječenje
Management
Neutropenija
Management
Postupak kod predoziranja
Management
Postupanje kod predoziranja
Management
Prekid liječenja
Management
Terapija
Management
Terapijski pristup
Management
Zbrinjavanje:
Management in case of clinical deterioration of PAH
Zbrinjavanje u slučaju kliničkog pogoršanja PAH
Management of acute overdose with Levodopa/Carbidopa/Entacapone Orion therapy is similar to acute overdose with levodopa.
Zbrinjavanje akutnog predoziranja tijekom terapije Levodopa/Carbidopa/Entacapone Orionom slično je kao u slučaju akutnog predoziranja levodopom.
Management of adverse drug reactions
Postupanje u slučaju nuspojava
Management of compromised airways
Zbrinjavanje kompromitiranih dišnih putova
Management of endophthalmitis
liječenje endoftalmitisa
Management of fluids during treatment with Revestive
Prilagodba tekućina tijekom liječenja lijekom Revestive
Management of Haemolytic and aregenerative Anaemia (haemoglobin, bilirubin, haptoglobin, reticulocytes)
Postupak u slučaju hemolitičke i neregenerativne anemije (hemoglobin, bilirubin, haptoglobin, retikulociti)
Management of Haemolytic and aregenerative Anaemia (haemoglobin, bilirubin, haptoglobin, reticulocytes)
Postupak u slučaju hemolitičkoe i regenerativne anemije (hemoglobin, bilirubin, haptoglobin, retikulociti)
Management of Hepatic Toxicity (ALT or AST)
Postupak u slučaju intoksikacije jetre (ALT ili AST)
Management of hyperuricaemia with appropriate urate lowering therapy (ULT) should be instituted or optimised.
Potrebno je započeti ili optimizirati kontrolu hiperuricemije odgovarajućom terapijom za snižavanje urata (eng. urate lowering therapy, ULT).
Management of important anticholinergic side effects
Postupanje kod pojave značajnih antikolinergičkih nuspojava
Management of intraocular pressure
liječenje intraokularnog tlaka
Management of intravitreal injection related adverse events
Liječenje nuspojava povezanih s intravitrealnim injekcijama
Management of IRRs (all indications)
Zbrinjavanje reakcija na infuziju (sve indikacije)
Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations of Gazyvaro as outlined below (see also section 4.4).
Zbrinjavanje reakcija na infuziju može zahtijevati privremeni prekid primjene, smanjenje brzine infuzije ili obustavu liječenja lijekom Gazyvaro kako je navedeno u nastavku (vidjeti i dio 4.4).
Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations of Gazyvaro as outlined below.
Zbrinjavanje reakcija na infuziju može zahtijevati privremeni prekid primjene, smanjenje brzine infuzije ili obustavu liječenja lijekom Gazyvaro kako je navedeno u nastavku.
Management of IVT injection related adverse events
Praćenje nuspojava povezanih uz intravitrealno ubrizgavanje
Management of IVT injection related adverse events
Zbrinjavanje štetnih događaja povezanih s IVT injekcijom
Management of myelosuppression and associated complications
Liječenje mijelosupresije i povezanih komplikacija
Management of neurotoxicity (including dose adjustment and dose interruption)
Zbrinjavanje neurotoksičnosti (uključujući prilagodbu doze i privremeni prekid doziranja).
Management of Neutropenia (neutrophil counts)
Postupak u slučaju neutropenije (broj neutrofila)
Management of overdose should be directed at maintaining vital functions.
Liječenje predoziranja treba biti usmjereno održavanju vitalnih funcija.
Management of overdose situations
Liječenje predoziranja
Management of overdose situations
Zbrinjavanje situacija predoziranja
Management of overdose situations and haemorrhage
Liječenje predoziranja i zbrinjavanje krvarenja
Management of overdose situations and haemorrhage
postupanje u slučaju predoziranja i krvarenja
Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian.
Ublažavanje perioperativnih bolova nastalih zbog ortopedskih ili operacija mekih tkiva: jedna doza 2 sata prije operacije, a nakon nje još 3 do 7 dana liječenja, zavisno o mišljenju nadležnog veterinara.
Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of your veterinary surgeon.
Ublažavanje perioperativnih bolova nastalih zbog ortopedskih ili operacija mekih tkiva: jedna doza 2 sata prije operacije, a nakon nje još 3 do 7 dana liječenja, zavisno o mišljenju vašega veterinara.
Management of Protein-Loss Syndrome (Albuminemia and/or UPC)
Postupak u slučaju sindroma gubitka bjelančevina (albuminemija i/ili UPC)
Management of Protein-Loss Syndrome (Albuminemia and/or UPC)
Upravljanje sindromom manjka proteina (Albuminemija i/ili UPC)
Management of side effects may require interruption, dose reduction, or discontinuation of therapy with Vargatef (see section 4.2).
Zbrinjavanje nuspojava može zahtijevati privremeni prekid, smanjenje doze ili trajni prekid terapije Vargatefom (vidjeti dio 4.2).
Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.
Liječenje takvih bolesnika potrebno je povjeriti liječnicima s iskustvom u liječenju hemofilije i inhibitora faktora VIII.
Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.
Liječenje tih bolesnika treba prepustiti liječnicima s iskustvom u liječenju hemofilije i inhibitora faktora VIII.
Management of such patients should be directed by physicians with experience in the care of patients with haemophilia, see also 4.4.
Liječenje ovih pacijenata trebaju voditi liječnici s iskustvom u liječenju pacijenata s hemofilijom, također vidjeti dio 4.4.
Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of CABOMETYX therapy (see Table 1).
Zbrinjavanje suspektnih nuspojava lijeka može zahtijevati privremeno prekidanje terapije CABOMETYXOM i/ili smanjenje doze (vidjeti Tablicu 1).
Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of COMETRIQ therapy.
Zbrinjavanjemogućih nuspojava na lijek može zahtijevati privremeni prekid i/ili smanjenje doze terapije lijekom COMETRIQ.
Management of suspected adverse reactions may require temporary interruption and/or dose reduction of temsirolimus therapy according to the guidelines in the following tables.
Liječenje sumnjivih nuspojava može zahtijevati privremeni prekid terapije i/ili smanjenje doze temsirolimusa sukladno smjernicama u sljedećim tablicama.
Management of suspected adverse reactions may require temporary interruption and/or dose reduction of temsirolimus therapy.
Liječenje nuspojava za koje postoji sumnja može zahtijevati privremeni prekid terapije i/ili sniženje doze temsirolimusa.
Management of symptomatic adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of Kadcyla as per guidelines provided in text and Tables 1 to 5.
Liječenje simptomatskih nuspojava može zahtijevati privremeni prekid liječenja, smanjenje doze ili trajan prekid liječenja lijekom Kadcyla, u skladu sa smjernicama koje se navode u tekstu te u Tablicama 1-5.
Management of the overdose may require general supportive measures, along with gastric lavage, intravenous fluids, administration of activated charcoal and electrocardiogram monitoring.
Zbrinjavanje predoziranja može zahtjevati opće mjere, zajedno s lavažom želuca, primjenom intravenskih tekućina, aktivnog ugljena i praćenjem putem elektrokardiograma.
Management of the overdose may require general supportive measures, along with gastric lavage, intravenous fluids, administration of activated charcoal and electrocardiogram monitoring.
Zbrinjavanje predoziranja može zahtjevati opće mjere, zajedno s lavažom želuca, primjenom intravenskih tekućina, aktivnog ugljena te praćenje elektrokardiograma.
Management of these events may require either temporary interruption or discontinuation of BLINCYTO (see section 4.2).
Zbrinjavanje ovih događaja može zahtijevati bilo privremenu prekid bilo trajni prekid primjene lijeka BLINCYTO (vidjeti dio 4.2).
Management recommendations (any occurrence)
Preporuke za zbrinjavanje (svi događaji)
Management recommendations for diarrhoea or colitis are based on severity of symptoms (per NCI- CTCAE v3 severity grading classification).
Preporučeno liječenje proljeva ili kolitisa temelji se na težini simptoma (klasifikacija težine prema NCI-CTCAE v3).
Management: Interruption of pazopanib and/or dose reduction should be combined with treatment of hypertension (if present, refer to hypertension warning section above) in patients with significant reductions in LVEF, as clinically indicated.
Zbrinjavanje: Prekid liječenja pazopanibom i/ili smanjenje doze treba kombinirati s liječenjem hipertenzije (ukoliko je prisutna, pogledati upozorenje za hipertenziju u prethodnom dijelu teksta) u bolesnika sa značajnim smanjenjem LVEF, prema kliničkoj indikaciji.
ManagementTelmisartan is not removed by haemodialysis.
Telmisartan se ne uklanja hemodijalizom.
mania (excessive or unreasonable enthusiasm),
manija (pretjerano ili bezrazložno ushićenje),
mania, agitation, depression, anxiety
manija, agitacija, depresija, anksioznost
Mania, bipolar disorders, homicidal ideation
manija, bipolarni poremećaji, pomisao na ubojstvo
Mania/hypomania*
Manija/hipomanija
Manic episodes associated with bipolar I disorder is a condition with symptoms such as feeling “high”, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Manične epizode povezane s bipolarnim poremećajem tipa I su bolest koju prate simptomi poput osjećaja ushićenja, prekomjerne količine energije, puno manje potrebe za snom nego je uobičajeno, vrlo brzog govora s ubrzanim tijekom misli te ponekad jake razdražljivosti.
Manic episodes in Bipolar I Disorder
Manične epizode u bipolarnom poremećaju tipa I
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals.
Manične epizode u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih: preporučena doza za ABILIFY je 10 mg/dan primijenjena jedanput dnevno neovisno o obroku.
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for Aripiprazole Accord is 10 mg/day administered on a once-a-day schedule without regard to meals.
Manične epizode u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih: preporučena doza za Aripiprazol Accord je 10 mg/dan primijenjena jedanput dnevno neovisno o obroku.
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for aripiprazole is 10 mg/day administered on a once-a-day schedule without regard to meals.
Manične epizode u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih: preporučena doza za Aripiprazole Mylan Pharma je 10 mg/dan primijenjena jedanput dnevno neovisno o obroku.
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for Aripiprazole Sandoz is 10 mg/day administered on a once-a-day schedule without regard to meals.
Manične epizode u bipolarnom poremećaju tipa I u adolescenata u dobi od 13 godina i starijih: preporučena doza za Aripiprazol Sandoz je 10 mg/dan primijenjena jedanput dnevno neovisno o obroku.
Manic episodes in Bipolar I Disorder in children and adolescents
Manične epizode u bipolarnom poremećaju tipa I u djece i adolescenata
Manic episodes in Bipolar I Disorder in children and adolescents with oral aripiprazole
Manične epizode u bipolarnom poremećaju tipa I u djece i adolescenata s peroralnim aripiprazolom
Manic episodes in Bipolar I Disorder with oral aripiprazole
Manične epizode u bipolarnom poremećaju tipa I kod oralno primijenjenog aripiprazola
Manic episodes in Bipolar I Disorder: the recommended starting dose for ABILIFY is 15 mg (i.e.
Manične epizode u bipolarnom poremećaju tipa I: preporučena početna doza za ABILIFY je 15 mg (tj.
Manic episodes in Bipolar I Disorder: the recommended starting dose for Aripiprazole Sandoz is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
Manične epizode u bipolarnom poremećaju tipa I: preporučena početna doza za Aripiprazol Sandoz je 15 mg i primjenjuje se jedanput dnevno neovisno o obrocima u obliku monoterapije ili kombinirane terapije (vidjeti dio 5.1).
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabeted mellitus with documented target organ damage
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti), ili dijabetes melitus tip 2 s dokazanim oštećenjem ciljnih organa.
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti) ili dijabetes melitus tip 2 s dokazanim oštećenjem ciljnih organa
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti) ili dijabetes melitus tip 2 s dokazanim oštećenjem ciljnih organa.
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti) ili šećernom bolešću tipa 2 s dokazanim oštećenjem ciljnih organa.
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti), ili dijabetes melitus tip 2 s dokazanim oštećenjem ciljnih organa.
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti) ili dijabetes melitus tip 2 s dokazanim oštećenjem ciljnih organa.
manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.
manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca, moždanog udara ili periferne arterijske bolesti) ili šećernom bolešću tipa 2 s dokazanim oštećenjem ciljnih organa.
Manifestations of hypersensitivity have been reported uncommonly in both clinical and post-marketing settings.
U kliničkim ispitivanjima, kao i u razdoblju nakon stavljanja lijeka u promet, manje su često prijavljene reakcije preosjetljivosti.
Mannheimia haemolytica (n=50)
Mannheimia haemolytica (n=-50)
Mannide mono oleate (Arlacel A) 46 l,
Manid monooleat (Arlacel A) 46 l
Mannitol
Ljudski albumin manitol
Mannitol (E 421)
manitol (E 421)
Mannitol (E 421) Nitrogen
manitol (E 421) dušik
Mannitol (E421) Carbomer Sodium chloride Tyloxapol Disodium edetate
manitol (E421) karbomer natrijev klorid tiloksapol dinatrijev edetat
Mannitol (E421) Glycine (E640) Sodium chloride
manitol (E421) glicin (E640) natrijev klorid
Mannitol (E421) Sucralose Xanthan gum
manitol (E421) sukraloza ksantanska guma
Mannitol (E421) Sucrose
manitol (E421) saharoza
Mannitol (E421), maize starch, low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate
Manitol (E421), kukuruzni škrob, djelomično supstituirana hidroksipropilceluloza, hidroksipropilceluloza, magnezijev stearat
Mannitol (E421), sucrose, l-histidine, hydrochloric acid (for pH adjustment) and polysorbate 20.
Manitol (E421), saharoza, L-histidin, kloridna kiselina (za podešavanje pH) i polisorbat 20.
Mannitol Citric acid
manitol
Mannitol Disodium edetate Sodium citrate
Manitol Dinatrijev edetat Natrijev citrat
Mannitol E 421 Microcrystalline cellulose Aspartame E 951 Crospovidone Magnesium stearate
manitol (E 421) celuloza, mikrokristalična aspartam (E 951) krospovidon magnezijev stearat
Mannitol E 421 Microcrystalline cellulose Aspartame E 951 Crospovidone Magnesium stearate
manitol (E421) celuloza, mikrokristalična aspartam (E951) krospovidon magnezijev stearat